On February 4, 2020 Samus Therapeutics, Inc. ("Samus" or the "Company"), a privately held, Boston-based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, reported that Dick Bagley, President and Interim Chief Executive Officer, will present at the BIO CEO & Investor Conference in New York on Tuesday, February 11 at 9:15 a.m. ET (Press release, Samus Therapeutics, FEB 4, 2020, View Source;investor-conference-300998025.html [SID1234553850]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!